Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
DarioHealth presents an integrated digital health platform aimed at the comprehensive management of chronic conditions over the long term, focusing on areas such as cardiometabolic health (including diabetes, hypertension, and weight), musculoskeletal issues, and mental health. By merging connected consumer devices with a user-friendly mobile application, real-time human coaching, and AI-enhanced behavior modification pathways, the platform adopts a “one platform, one coach, one experience” philosophy. This allows users to effectively track important health metrics like blood glucose levels, blood pressure, body weight, and also monitor their exercise routines, dietary choices, and emotional well-being. Users benefit from tailored interventions that adapt to their evolving health needs, ensuring a personalized journey toward better health. With a foundation built on clinical validation, the platform boasts reported outcomes such as marked improvements in A1c levels, reductions in blood pressure categories, and decreases in BMI, while also addressing pain relief and posture enhancement in musculoskeletal health, alongside alleviation of anxiety and depressive symptoms in mental health. Overall, DarioHealth provides a holistic approach to chronic condition management that empowers users to take charge of their health journey.
Description
Introducing a versatile API designed to seamlessly integrate with your diabetes management system, offering tailored therapeutic education and enhanced insights into blood glucose level fluctuations. This solution enables real-time risk predictions, fostering greater personalization and improved system regulation, while adeptly managing complex living scenarios characterized by rapid glucose variations. With advancements in telemedicine and retrospective analysis, patients receive robust decision-support tools. Currently, Hillo is developing the next iterations of its AI technology, which includes a therapeutic recommendation system aimed at preventing hypoglycemia and hyperglycemia, anticipated to achieve CE mark class IIB by 2020. Additionally, a new generation of the artificial pancreas is projected for release in 2021, addressing key limitations of existing systems through ultra-personalization driven by machine learning. This innovative approach marks the introduction of the first self-learning artificial intelligence capable of predicting blood glucose levels, aiming to secure a CE mark as a medical device, thereby transforming diabetes management for users. In essence, Hillo's advancements could significantly enhance the quality of life for individuals managing diabetes.
API Access
Has API
No
API Access
Has API
Yes
Integrations
No details available.
Integrations
No details available.
Pricing Details
Free
Free Trial
No
Free Version
Yes
Pricing Details
No price information available.
Free Trial
Yes
Free Version
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
Yes
iPad App
No
Android App
Yes
Windows
No
Mac
No
Linux
No
Chromebook
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Customer Support
Business Hours
Yes
Live Rep (24/7)
No
Online Support
Yes
Customer Support
Business Hours
No
Live Rep (24/7)
No
Online Support
Yes
Types of Training
Training Docs
Yes
Webinars
Yes
Live Training (Online)
Yes
In Person
No
Types of Training
Training Docs
Yes
Webinars
No
Live Training (Online)
No
In Person
Yes
Vendor Details
Company Name
DarioHealth
Country
United States
Website
www.dariohealth.com
Vendor Details
Company Name
Hillo
Country
France
Website
www.hillo.ai/